Tuesday , September 25 2018
Home / Resources / Articles / Survey Says: Your Thoughts in 2017

Survey Says: Your Thoughts in 2017

Dec 30, 2017
 

In 2017, we offered weekly survey questions on topics ranging from standard tests, to new drugs, to opinions on CGMs, to personal exercise habits – and you answered. Here are the survey questions that drew the most response this year.

What would you like your A1c to be, regardless of your health? (This question is a favorite of our Publisher Steve Freed, and clearly of DIC readers as well: it had the highest number of responses this year, by a considerable margin.)

7% A1c: 8%

6% A1c: 20%

5% A1c: 56%

4% A1c: 12%

Questions on the basics of treatment – diagnosing prediabetes, diet, exercise, and when to prescribe metformin — were another popular category.

Would you treat a patient with an A1c of 5.7-5.9%, who has diabetes in their family history and is a few pounds overweight with elevated cholesterol, with metformin along with diet and exercise, or just diet and exercise to get started?

Just diet and exercise: 59%

Diet, exercise, and metformin: 40%

Which class of drugs would you prefer for a person with an A1c of 5.6%?

Just diet and exercise: 76%

GLP-1: 4%

Metformin: 20%

At what A1c level would you recommend the use of metformin?

A1c 5.6%: 10%

A1c 5.7-5.9%: 28%

A1c 6.0%: 16%

A1c 6.1-6.2%: 6%

A1c 6.3-6.4%: 6%

A1c 6.5-7.0%: 33%

Which test do you use to determine if a patient has prediabetes?

Fasting blood sugar: 27%

A1c: 46%

OGTT: 24%

Random blood sugar: 3%

What percent of your prediabetes patients are on metformin?

0% of patients: 4%

10% of patients: 18%

25% of patients: 28%

50% of patients: 20%

75% of patients: 30%

Overall, our respondents indicated positive experiences with & opinions of SGLT-2 inhibitor drugs.

Which new drug class have you seen the best results with in lowering A1c’s?

DPP-4s: 13%

GLP-1s: 13%

SGLT-2s: 68%

Other: 5%

For a patient newly diagnosed with type 2 and an elevated A1c of 7-8%, would you consider an SGLT-2 drug as a second treatment option added to metformin if they are not at goal on metformin?

Yes: 67%

Likely: 15%

No: 17%

CGMs were a huge topic of conversation in 2017; DIC readers’ opinions on their impact  are mixed.

Do you believe that glucose monitors will be a thing of the past as continuous glucose monitors (CGM) become less expensive and more accurate?

Yes: 39%

No: 39%

Not sure: 23%

And finally, many of you were eager to share your experience — or lack thereof — with Editor Dave Joffe’s favorite exercise, riding a bike.  Results were, shall we say, all over the map.

When was the last time you rode a bike?

Hours: 19%

Days: 19%

Weeks: 2%

Months: 19%

Years: 14%

Decades: 17%

Never: 10%

Thank you to our wonderful readers for all their contributions to making DIC a success in 2017!